On February 6, 2026, VolitionRx received a notice from NYSE American stating non-compliance with continued listing standards in Section 1003(a)(i)-(iii), as it reported losses from continuing operations and lacks the required stockholders’ equity of at least $2 million for two years, $4 million for three years and $6 million for five years. The notice also confirms ineligibility for exemptions, including the market capitalization exemption for companies over $50 million.

VolitionRx must submit a plan by March 8, 2026 detailing actions to regain compliance with listing standards by August 6, 2027. If accepted, the plan will be subject to quarterly monitoring and the company’s shares will carry a ".BC" designation until standards are fully met.

Failure to submit an acceptable plan or to achieve compliance by the August 6, 2027 deadline will trigger delisting proceedings under Section 1010 and Part 12 of the NYSE American Company Guide. The company retains the right to appeal any delisting determination through the prescribed exchange procedures.